RMTI Stock Analysis: Buy, Sell, or Hold?
RMTI - Rockwell Medical, Inc. (DE) Common Stock
$0.79
0.00 (-0.55%)
▼
5d:
-5.0%
30d:
-13.55%
90d:
-21.57%
HOLD
MODERATE Confidence
Analysis Updated: May 15, 2026 12:00 AM ET
Earnings: May 07, 2026
0d
Get Alerted When RMTI Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
1 traders called RMTI this week
100% bullish • 0 bearish
100% bullish • 0 bearish
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: RMTI shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
📊 HOLD: RMTI shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
In-depth Analysis How we analyze
Valuation Analysis: RMTI is currently trading at $0.79, which is considered oversold relative to its 30-day fair value range of $0.82 to $0.92. From a valuation perspective, the stock is trading at a discount (Forward PE: 15.8) compared to its historical average (19.0). Remarkably, the market is currently pricing in an annual earnings decline of 5.9% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, RMTI is in a uptrend. Immediate support is located at $0.74, while resistance sits at $0.92.
Market Sentiment: RMTI has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $3.00 (+278.7%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, RMTI is in a uptrend. Immediate support is located at $0.74, while resistance sits at $0.92.
Market Sentiment: RMTI has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $3.00 (+278.7%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$0.82 -
$0.92
Company Quality Score
53/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
57.1%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 278.7% below Wall St target ($3.00)
- CAUTION: 5-day price weakness (-5.0%) - monitor closely
Trading Range Analysis
30-Day Trading Range
$0.82 -
$0.92
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$0.74
Resistance Level
$0.92
Current Trend
Uptrend
Technical data as of
May 15, 2026
Fundamental Context
Forward P/E (Next Year Est.)
15.84
Wall Street Target
$3.00
(+278.7%)
Revenue Growth (YoY)
-25.6%
Profit Margin
-7.7%
Valuation Discount vs History
-5.9% cheaper
PE vs Historical
15.8 vs 19.0
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-5.9%
(market-implied from PE analysis)
1-Year Target
$0.75
(-6%)
2-Year Target
$0.70
(-12%)
3-Year Target
$0.66
(-17%)
3-Yr Target (if PE normalizes)
(PE: 16→19)
$0.79
(0%)
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 15.8 to 19.0
Stabilization Target:
$0.95
(+19.9%)
PE Expansion Potential:
+19.9%
Share & Embed Analysis
Last updated: May 18, 2026 9:38 AM ET
Data refreshes hourly during market hours. Next update: 10:38 AM
Data refreshes hourly during market hours. Next update: 10:38 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is RMTI showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
25 analysts |
$191 | 63 BUY |
|
ZTS
Zoetis Inc |
STRONG BUY
19 analysts |
$131 | 57 HOLD |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$104 | 59 HOLD |
|
AQST
Aquestive Therapeutics I… |
STRONG BUY
9 analysts |
$9 | 65 BUY |
|
BCRX
BioCryst Pharmaceuticals… |
STRONG BUY
12 analysts |
$22 | 58 HOLD |
